American Journal of Cardiology
Volume 105, Issue 1 , Pages 133-135 , 1 January 2010

Safety of Regadenoson in Patients with End-Stage Renal Disease

  • Wael Aljaroudi, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • Corresponding Author InformationCorresponding author: Tel: (205) 934-0545; fax: (205) 934-7579
    • ,
  • Daniel Hermann, MD

      Affiliations

    • Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Fadi Hage, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • Section of Cardiology, Birmingham Veterans Affairs Medical Center, Birmingham, Alabama
    • ,
  • Jaekyeong Heo, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
    • ,
  • Ami E. Iskandrian, MD

      Affiliations

    • Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama

Received 30 June 2009 ,Revised 4 August 2009 ,Accepted 4 August 2009.

  • Image Result

    Hemodynamic changes associated with regadenoson. (Left) Bars represent percent changes with SDs. (Right) Bars represent absolute changes with SDs. ADVANCE MPI, Adenosine versus regadenoson comparative

    Hemodynamic changes associated with regadenoson. (Left) Bars represent percent changes with SDs. (Right) Bars represent absolute changes with SDs. ADVANCE MPI, Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Phase 3 trial; bmp, beats per minute; DBP, diastolic blood pressure; SBP, systolic blood pressure.

 Dr. Iskandrian is a consultant to Gilead Sciences, Inc., Foster City, California, and to Astellas Pharma Global Development, Inc., Deerfield, Illinois.

PII: S0002-9149(09)02228-0

doi: 10.1016/j.amjcard.2009.08.663

American Journal of Cardiology
Volume 105, Issue 1 , Pages 133-135 , 1 January 2010

Article Tools

* Image Usage & Resolution